PT - JOURNAL ARTICLE AU - Jing Wei AU - Yuhang Huan AU - Ziqi Heng AU - Chenyang Zhao AU - Youhe Gao TI - Dynamic urine proteome changes in a rat model of simvastatin-induced skeletal muscle injury AID - 10.1101/2021.06.10.447866 DP - 2021 Jan 01 TA - bioRxiv PG - 2021.06.10.447866 4099 - http://biorxiv.org/content/early/2021/06/10/2021.06.10.447866.short 4100 - http://biorxiv.org/content/early/2021/06/10/2021.06.10.447866.full AB - Background Statin-associated muscle symptoms (SAMS) are the main side effects of statins. Currently, there are no effective biomarkers for accurate clinical diagnosis. Urine is not subject to homeostatic control and therefore accumulates early changes, making it an ideal biomarker source. We therefore examined urine proteome changes associated with SAMS in an animal model.Methods Here, we established a SAMS rat model by intragastric intubation with simvastatin (80 mg/kg). Biochemical analyses and hematoxylin and eosin (H&E) staining were used to evaluate the degree of muscle injury. The urine proteome on days 3, 6, 9 and 14 was profiled using liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) with the data-independent acquisition (DIA) method.Results Differential proteins on day 14 of SAMS were mainly associated with glycolysis/gluconeogenesis, pyruvate metabolism, metabolism of reactive oxygen species and apoptosis, all of which were reported to be associated with the pathological mechanism of SAMS. Among the 14 differentially expressed proteins on day 3, FIBG, OSTP and CRP were associated with muscle damage, while EHD1, CUBN and FINC were associated with the pathogenic mechanisms of SAMS. MYG and PRVA increased dramatically compared with CK elevation in serum on day 14 of SAMS.Conclusions Our preliminary results indicated that the urine proteome can reflect early changes in the SAMS rat model, providing the potential for monitoring drug side effects in future clinical research.Competing Interest StatementThe authors have declared no competing interest.